Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The Treg cell-based therapies pipeline shows robust development with 29+ pharmaceutical companies actively working on 35+ therapies across various clinical stages. Key players including Orca Bio, Cellenkos, Quell Therapeutics, GentiBio, and others are advancing promising candidates like Orca-T and CK0801, with approximately 2+ therapies in late-stage development and 10+ in mid and early stages. Recent developments include FDA clearances and clinical trial initiations across multiple companies.